Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-10-10
2011-12-13
Murray, Jeffrey (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000
Reexamination Certificate
active
08076354
ABSTRACT:
The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5and R2are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
REFERENCES:
patent: 5990146 (1999-11-01), Boschelli et al.
patent: 6465484 (2002-10-01), Bilodeau et al.
patent: 6498165 (2002-12-01), Armstrong et al.
patent: 7074801 (2006-07-01), Yoshida et al.
patent: 2002/0041880 (2002-04-01), DeFeo-Jones et al.
patent: 2004/0019210 (2004-01-01), Chivikas Connolly et al.
patent: 2004/0067948 (2004-04-01), Hallett
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 2004/0267510 (2004-12-01), Bemis et al.
patent: 2006/0035921 (2006-02-01), Castelhano et al.
patent: 2006/0089362 (2006-04-01), Seno et al.
patent: 2006/0116402 (2006-06-01), Crew et al.
patent: 2006/0189629 (2006-08-01), Bolger et al.
patent: 2007/0185140 (2007-08-01), Bordon-Pallier et al.
patent: 2008/0139606 (2008-06-01), Tabart et al.
patent: 1382603 (2004-01-01), None
patent: 1724258 (2006-11-01), None
patent: 1748048 (2007-01-01), None
patent: 1790650 (2007-05-01), None
patent: 1882475 (2008-01-01), None
patent: 2116543 (2009-11-01), None
patent: 2001-057292 (2001-02-01), None
patent: 2004-002826 (2004-01-01), None
patent: 95/35296 (1995-12-01), None
patent: 96/34866 (1996-11-01), None
patent: 97/12613 (1997-04-01), None
patent: 98/03510 (1998-01-01), None
patent: 98/54093 (1998-12-01), None
patent: 99/38868 (1999-08-01), None
patent: 00/12089 (2000-03-01), None
patent: 00/53605 (2000-09-01), None
patent: 01/00207 (2001-01-01), None
patent: 01/00213 (2001-01-01), None
patent: 01/00214 (2001-01-01), None
patent: 01/14375 (2001-03-01), None
patent: 01/18000 (2001-03-01), None
patent: 01/21634 (2001-03-01), None
patent: 01/38326 (2001-05-01), None
patent: 01/66098 (2001-09-01), None
patent: 02/12238 (2002-02-01), None
patent: 02/34748 (2002-05-01), None
patent: 02/38569 (2002-05-01), None
patent: 02/46168 (2002-06-01), None
patent: 02/066477 (2002-08-01), None
patent: 02/066478 (2002-08-01), None
patent: 02/066480 (2002-08-01), None
patent: 02/066481 (2002-08-01), None
patent: 02/074773 (2002-09-01), None
patent: 02/080914 (2002-10-01), None
patent: 03/007955 (2003-01-01), None
patent: 03/048132 (2003-06-01), None
patent: 03/092595 (2003-11-01), None
patent: 03/099811 (2003-12-01), None
patent: 03/099816 (2003-12-01), None
patent: 03/099817 (2003-12-01), None
patent: 03/101993 (2003-12-01), None
patent: 2004/026867 (2004-04-01), None
patent: 2004/035579 (2004-04-01), None
patent: 2004/052286 (2004-06-01), None
patent: 2004/052315 (2004-06-01), None
patent: 2004/087153 (2004-10-01), None
patent: 2005/021531 (2005-03-01), None
patent: 2005/054230 (2005-06-01), None
patent: 2005/075470 (2005-08-01), None
patent: 2006/000420 (2006-01-01), None
patent: 2006/034402 (2006-03-01), None
patent: 2006/038001 (2006-04-01), None
patent: 2006/070198 (2006-07-01), None
patent: 2006/091671 (2006-08-01), None
patent: 2006/094235 (2006-09-01), None
patent: 2006/135667 (2006-12-01), None
patent: 2007/036732 (2007-04-01), None
patent: 2007/109362 (2007-09-01), None
patent: 2007/112093 (2007-10-01), None
patent: 2008/003511 (2008-01-01), None
patent: 2008/008747 (2008-01-01), None
patent: 2008/075068 (2008-06-01), None
patent: 2008/078091 (2008-07-01), None
patent: 2008/078100 (2008-07-01), None
patent: 2008/081910 (2008-07-01), None
patent: 2008/124323 (2008-10-01), None
patent: 2008/154642 (2008-12-01), None
patent: 2009/002534 (2008-12-01), None
patent: 2009/047506 (2009-04-01), None
patent: 2009/047522 (2009-04-01), None
patent: 2009/150240 (2009-12-01), None
patent: 2010/119284 (2010-10-01), None
patent: 2010/119285 (2010-10-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Vippagunta et. al. Advanced Drug Delivery Reviews 48 (2001) 3-26.
Search Report for GB0625827.1 dated Apr. 25, 2007.
Search Report for GB0719998.7 dated Nov. 12, 2007.
Search Report for PCT/GB2007/004960 dated Sep. 22, 2008.
Search Report for GB0625826.3 dated Apr. 25, 2007.
Search Report for GB0720000.9 dated Nov. 12, 2007.
Search Report for PCT/GB2007/004934 dated May 6, 2008.
Search Report for GB0810902.7 dated Sep. 17, 2008.
Search Report for PCT/EP2009/057318 dated Oct. 12, 2009.
Search Report for GB0720038.9 dated Apr. 17, 2008.
Search Report for PCT/GB2008/003439 dated Jan. 29, 2009.
Search Report for GB0720041.3 dated Apr. 17, 2008.
Search Report for PCT/GB2008/003418 dated Jan. 29, 2009.
Search Report for GB0906472.6 dated Jul. 7, 2009.
Search Report for PCT/GB2010/050617 dated Jul. 20, 2010.
Search Report for GB0906470.0 dated Jul. 8, 2009.
Search Report for PCT/GB2010/050618 dated Jul. 23, 2010.
Bilodeau, Mark T. et al., Design and Synthesis of 1,5-Dairylbenzimidazoles as Inhibitors of the VEGF-Receptor KDR, Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 2485-2488.
Clark, Michael P. et al., Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3), Bioorganic & Medicinal Chemistry Letters 17 (5), 2007, pp. 1250-1253.
Wermuth, Camille G., Molecular Variations Based on Isosteric Replacements, The Practice of Medicinal Chemistry, 1996, pp. 203-237.
Fraley, Mark E. et al., Synthesis and Initial SAR Studies of 3,6-Disubstituted Pyrazolo[1,5-α]pyrimidines: A New Class of KDR Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 2767-2770.
Wu, Zhicai et al., Design and Synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR, Bioorganic & Medicinal Chemistry Letters 14, 2004, pp. 909-912.
Fraley, Mark E. et al., Optimization of a Pyrazolo[1,5-α]pyrimidine Class of KDR Kinase Inhibitors: Improvements in Physical Properties Enhance Cellular Activity and Pharmacokinetics, Bioorganic & Medicinal Chemistry Letters 12, 2002, pp. 3537-3541.
Skaper, Stephen D. et al., The FGFR1 Inhibitor PD 173074 Selectively and Potently Antagonizes FGF-2 Neurotrophic and Neurotropic Effects, Journal of Neurochemistry, 2000, pp. 1520-1527.
Mohammadi, Moosa et al., Crystal structure of an angiogenesis inhibitor bound to the FGR receptor tyrosine kinase domain, The EMBO Journal, vol. 17, No. 20, 1998, pp. 5896-5904.
Connolly, Cleo J.C. et al., Discovery and Structure-Activity Studies of a Novel Series of Pyrido[2,3-d]Pyrimidine Tyrosine Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 18, 1997, pp. 2415-2420.
Hamby, James M. et al., Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors, J. Med. Chem, 40, 1997, pp. 2296-2303.
Scribner, Andrew et al., Synthesis and biological activity of imidazopyridine anticoccidial agents: Part I, European Journal of Medicinal Chemistry 42, 2007, pp. 1334-1357.
Anderson, Malcolm et al., Imidazo[1,2-α]pyridines: A Potent and Selective Class of Cyclin-Dependent Kinase Inhibitors Identified Through Structure-Based Hybridisation, Bioorganic & Medicinal Chemistry Letters 13, 2003, pp. 3021-3026.
Mohammadi, Moosa et al., Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors, Science, 276, 1997, pp. 955-960.
Dorwald, F. Zaragoza, Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface.
Vippagunta, Sudha R., et al., Crystalline solids, Advanced Drug Delivery Reviews 48, 2001, pp. 3-26.
Berdini Valerio
Besong Gilbert Ebai
Carr Maria Grazia
Griffiths-Jones Charlotte Mary
Murray Christopher William
Astex Therapeutics Limited
Heslin Rothenberg Farley & & Mesiti P.C.
Murray Jeffrey
LandOfFree
Bicyclic heterocyclic compounds as protein tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic heterocyclic compounds as protein tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocyclic compounds as protein tyrosine kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4297288